Subclinical Atherosclerosis Noted in Diffuse Scleroderma PDF Print E-mail
Saturday, 15 September 2012 14:29
Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical atherosclerosis, according to a study published online Aug. 16 in Arthritis Care & Research.

To identify signs of early cardiovascular involvement in SSc, Maurizio Turiel, M.D., of the University of Milan, and colleagues conducted a pilot study involving 20 patients with diffuse SSc but no signs of cardiovascular disease, and 20 age- and gender-matched control patients. The researchers found that arterial wall measurements were significantly different in SSc versus control patients.

Compared with controls, in SSc patients, right and left carotid intima-media thickness, pulse wave velocity, and stiffness index β were also significantly elevated. Coronary flow reserve was significantly lower and plasma levels of asymmetric dimethylarginine levels were significantly higher in those with SSc compared with healthy controls. "In conclusion, patients with diffuse SSc seem to have subclinical cardiovascular involvement, as demonstrated by various methods," the authors write. "Further studies are required to define more precise algorithms for assessing and managing cardiovascular disease in SSc patients."

Source: Healthday (2012), "Subclinical Atherosclerosis Noted in Diffuse Scleroderma"; Original article can be viewed here.

 
More articles :

» 7 Tips For Balancing Rest and Activity

I wanted to help patients and my friends by sharing some helpful tips about Scleroderma, an autoimmune disease in which the body attacks itself by destroying its own cells and functions. The effects of are quite severe and can affect a patient’s...

» PUVA Therapy In The Treatment of Localized Scleroderma

In localized , disease activity would tend to stop spontaneously over time. Treatment is important to reduce disabilities caused by the active phases of disease. According to , there are three treatments used in the treatment of localized...

» Mixed Connective Tissue Disease May Represent Subset of Systemic Scleroderma

Many patients with (MCTD) may represent a subset of Systemic , rather than a disease involving overlapping connective tissue disorders as is commonly believed, or a subset of Lupus as some have suggested over the years, Dr. Virginia Steen said at...

» Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants

Systemic sclerosis is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal...

» Cytokines in Systemic Sclerosis: Focus on IL-17

Julie Baraut, Dominique Farge, Elena Ivan-Grigore, Franck Verrecchia, and Laurence MichelSystemic sclerosis (SSc) is an autoimmune disease characterized by progressive sclerosis of the skin and internal organ dysfunction. Cytokine production and...

» Scientists Identify New Genetic Region Associated with Scleroderma

New research supported, in part, by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has identified a new genetic link to systemic sclerosis (also known as systemic scleroderma) and confirmed three previously...